{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:10:36Z","timestamp":1792440636482,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021081","name":"European Rare Kidney Disease Reference Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ekir.2024.12.033","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:26:54Z","timestamp":1735604814000},"page":"1020-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort"],"prefix":"10.1016","volume":"10","author":[{"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moglie","family":"Le Quintrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stehl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cornec-Le Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Courbebaisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Frouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Krummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Monet-Didailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rousset-Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Ryckewaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Schendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Flammier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Acquaviva-Bourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.12.033_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.12.033_bib2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria type 1: Indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.033_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: An expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib4","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ekir.2022.04.012","article-title":"Improved outcome of infantile oxalosis over time in Europe: Data from the OxalEurope registry","volume":"7","author":"Deesker","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.033_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-017-0105-8","article-title":"Correlation between the molecular effects of mutations at the dimer interface of alanine\u2013glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6","volume":"41","author":"Dindo","year":"2018","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2024.12.033_bib6","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/ckj\/sfab245","article-title":"Primary hyperoxaluria type 1: novel therapies at a glance","volume":"15","author":"Bacchetta","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2024.12.033_bib7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.12.033_bib8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.ekir.2024.12.033_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: Phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.12.033_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2021.12.001","article-title":"Randomized clinical trial on the long-term efficacy and safety of lumasiran in patients with primary hyperoxaluria Type 1","volume":"7","author":"Hulton","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.033_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ndt\/gfac295","article-title":"Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases","volume":"38","author":"Sellier-Leclerc","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.033_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.kint.2021.10.022","article-title":"Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy","volume":"101","author":"Joher","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.033_bib14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJMc2312941","article-title":"Lumasiran, isolated kidney transplantation, and continued vigilance","volume":"390","author":"Bacchetta","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.12.033_bib15","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.ekir.2023.07.025","article-title":"Determinants of kidney failure in primary hyperoxaluria Type 1: findings of the European hyperoxaluria consortium","volume":"8","author":"Metry","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.033_bib16","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ekir.2024.12.033_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ekir.2023.10.004","article-title":"Multicenter long-term real world data on treatment with lumasiran in patients with primary hyperoxaluria Type 1","volume":"9","author":"Martin-Higueras","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.033_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00467-022-05613-2","article-title":"Genetic assessment in primary hyperoxaluria: why it matters","volume":"38","author":"Mandrile","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00467-023-06268-3","article-title":"Nephrocalcinosis can disappear in infants receiving early lumasiran therapy","volume":"39","author":"Kayal","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00467-021-05393-1","article-title":"The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants","volume":"37","author":"M\u00e9aux","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/pan.12176","article-title":"Neonatal clinical pharmacology","volume":"24","author":"Allegaert","year":"2014","journal-title":"Pediatr Anesth"},{"key":"10.1016\/j.ekir.2024.12.033_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s004670050145","article-title":"Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure","volume":"10","author":"Hoppe","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib23","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00467-016-3324-6","article-title":"Pediatric combined liver-kidney transplantation: a single-center experience of 18 cases","volume":"31","author":"Duclaux-Loras","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00467-015-3048-z","article-title":"Bone impairment in primary hyperoxaluria: a review","volume":"31","author":"Bacchetta","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.033_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2023.01.029","article-title":"Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1","volume":"103","author":"Garrelfs","year":"2023","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492403482X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492403482X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:59:59Z","timestamp":1747285199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492403482X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S246802492403482X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.12.033","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}